478 related articles for article (PubMed ID: 11156401)
1. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
2. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
3. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
4. Growth arrest in G1 protects against oxygen-induced DNA damage and cell death.
Rancourt RC; Hayes DD; Chess PR; Keng PC; O'Reilly MA
J Cell Physiol; 2002 Oct; 193(1):26-36. PubMed ID: 12209877
[TBL] [Abstract][Full Text] [Related]
5. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta1 inhibits BRCA1 expression through a pathway that requires pRb.
Satterwhite DJ; Matsunami N; White RL
Biochem Biophys Res Commun; 2000 Sep; 276(2):686-92. PubMed ID: 11027532
[TBL] [Abstract][Full Text] [Related]
8. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
9. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
10. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
12. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
13. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor beta1 (TGF-beta1)-mediated p27Kip1 expression.
Yoon G; Kim HJ; Yoon YS; Cho H; Lim IK; Lee JH
Biochem J; 2002 Sep; 366(Pt 2):613-21. PubMed ID: 11945174
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
16. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
18. Effects of transforming growth factor beta 1 on the growth of rhabdomyosarcoma cell line RD.
Ye L; Zhang HY; Wang H; Yang GH; Bu H; Zhang L; Wang SL
Chin Med J (Engl); 2005 Apr; 118(8):678-86. PubMed ID: 15899124
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cell growth by TGF beta 1 is associated with inhibition of B-myb and cyclin A in both BALB/MK and Mv1Lu cells.
Satterwhite DJ; Aakre ME; Gorska AE; Moses HL
Cell Growth Differ; 1994 Aug; 5(8):789-99. PubMed ID: 7986745
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes.
Münger K; Pietenpol JA; Pittelkow MR; Holt JT; Moses HL
Cell Growth Differ; 1992 May; 3(5):291-8. PubMed ID: 1633111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
